Radar chart array analysis to visualize effects of formulation variables on IgG1 particle formation as measured by multiple analytical techniques

Journal of Pharmaceutical Sciences

Volumn 102, Issue 12, 2013, Pages 4256-4267

  Kalonia, Cavan ^a   Kumru, Ozan S ^a   Kim, Jae Hyun ^a   Middaugh, C Russell ^a   Volkin, David B ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

Archimedes; data visualization; formulation; microflow imaging; monoclonal antibody; morphology; particle size; protein aggregation; stability

Indexed keywords

IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; SODIUM CHLORIDE;

ANALYTIC METHOD; ARTICLE; DIGITAL IMAGING; ENVIRONMENTAL STRESS; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTERMETHOD COMPARISON; MECHANICAL STRESS; MICROFLOW DIGITAL IMAGING; MORPHOLOGY; PARTICLE SIZE; PH; PROTEIN AGGREGATION; PROTEIN CONFORMATION; RADAR CHART ARRAY ANALYSIS;

ARCHIMEDES; DATA VISUALIZATION; FORMULATION; MICROFLOW IMAGING; MONOCLONAL ANTIBODY; MORPHOLOGY; PARTICLE SIZE; PROTEIN AGGREGATION; STABILITY;

CALORIMETRY, DIFFERENTIAL SCANNING; CHROMATOGRAPHY, GEL; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOGLOBULIN G; MICROSCOPY; PARTICLE SIZE; PROTEIN CONFORMATION; PROTEIN STABILITY; SODIUM CHLORIDE; SPECTROMETRY, FLUORESCENCE;

EID: 84888199388     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23738     Document Type: Article

References (50)

1. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, Winter G, Fan YX, Kirshner S, Verthelyi D, Kozlowski S, Clouse KA, Swann PG, Rosenberg A, Cherney B,. 2009. Overlooking subvisible particles in therapeutic protein products: Gaps that may compromise product quality. J Pharm Sci 98 (4): 1201-1205.
2. Luo Q, Joubert MK, Stevenson R, Ketchem RR, Narhi LO, Wypych J,. 2011. Chemical modifications in therapeutic protein aggregates generated under different stress conditions. J Biol Chem 286 (28): 25134-25144.
3. Joubert MK, Luo Q, Nashed-Samuel Y, Wypych J, Narhi LO,. 2011. Classification and characterization of therapeutic antibody aggregates. J Biol Chem 286 (28): 25118-25133.
4. Filipe V, Jiskoot W, Basmeleh AH, Halim A, Schellekens H, Filipe V,. 2012. Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice. mAbs 4 (6): 740-752.
5. Scherer TM, Leung S, Owyang L, Shire SJ,. 2012. Issues and challenges of subvisible and submicron particulate analysis in protein solutions. AAPS J 14 (2): 236-243.
6. Liu L, Randolph TW, Carpenter JF,. 2012. Particles shed from syringe filters and their effects on agitation-induced protein aggregation. J Pharm Sci 101 (8): 2952-2959.
7. Ripple DC, Dimitrova MN,. 2012. Protein particles: What we know and what we do not know. J Pharm Sci 101 (10): 3568-3579.
8. Chi EY, Krishnan S, Randolph TW, Carpenter JF,. 2003. Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation. Pharm Res 20 (9): 1325-1336.
9. Philo JS, Arakawa T,. 2009. Mechanisms of protein aggregation. Curr Pharm Biotechnol 10 (4): 348-351.
10. Neudecker P, Robustelli P, Cavalli A, Walsh P, Lundstrom P, Zarrine-Afsar A, Sharpe S, Vendruscolo M, Kay LE,. 2012. Structure of an intermediate state in protein folding and aggregation. Science 336 (6079): 362-366.
11. Brummitt RK, Nesta DP, Chang L, Chase SF, Laue TM, Roberts CJ,. 2011. Nonnative aggregation of an IgG1 antibody in acidic conditions: Part 1. Unfolding, colloidal interactions, and formation of high-molecular-weight aggregates. J Pharm Sci 100 (6): 2087-2103.
12. Arosio P, Rima S, Morbidelli M,. 2013. Aggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: From oligomers to larger aggregates. Pharm Res 30 (3): 641-654.
13. Kroetsch AM, Sahin E, Wang HY, Krizman S, Roberts CJ,. 2012. Relating particle formation to salt- and pH-dependent phase separation of non-native aggregates of alpha-chymotrypsinogen A. J Pharm Sci 101 (10): 3651-3660.
14. Kim N, Remmele RL, Jr., Liu D, Razinkov VI, Fernandez EJ, Roberts CJ,. 2013. Aggregation of anti-streptavidin immunoglobulin gamma-1 involves Fab unfolding and competing growth pathways mediated by pH and salt concentration. Biophys Chem 172: 26-36.
15. Gokarn YR, Fesinmeyer RM, Saluja A, Razinkov V, Chase SF, Laue TM, Brems DN,. 2011. Effective charge measurements reveal selective and preferential accumulation of anions, but not cations, at the protein surface in dilute salt solutions. Protein Sc 20 (3): 580-587.
16. Fesinmeyer RM, Hogan S, Saluja A, Brych SR, Kras E, Narhi LO, Brems DN, Gokarn YR,. 2009. Effect of ions on agitation- and temperature-induced aggregation reactions of antibodies. Pharm Res 26 (4): 903-913.
17. Das TK., 2012. Protein particulate detection issues in biotherapeutics development-current status. AAPS Pharm Sci Tech 13 (2): 732-746.
18. Narhi LO, Jiang Y, Cao S, Benedek K, Shnek D,. 2009. A critical review of analytical methods for subvisible and visible particles. Curr Pharm Biotechnol 10 (4): 373-381.
19. Demeule B, Messick S, Shire SJ, Liu J,. 2010. Characterization of particles in protein solutions: Reaching the limits of current technologies. AAPS J 12 (4): 708-715.
20. Zolls S, Tantipolphan R, Wiggenhorn M, Winter G, Jiskoot W, Friess W, Hawe A,. 2012. Particles in therapeutic protein formulations, part 1: Overview of analytical methods. J Pharm Sci 101 (3): 914-935.
21. Kumru OS, Liu J, Ji JA, Cheng W, Wang YJ, Wang T, Joshi SB, Middaugh CR, Volkin DB,. 2012. Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags. J Pharm Sci 101 (10): 3636-3650.
22. Sharma DK, King D, Oma P, Merchant C,. 2010. Micro-flow imaging: Flow microscopy applied to sub-visible particulate analysis in protein formulations. AAPS J 12 (3): 455-464.
23. Barnard JG, Singh S, Randolph TW, Carpenter JF,. 2011. Subvisible particle counting provides a sensitive method of detecting and quantifying aggregation of monoclonal antibody caused by freeze-thawing: Insights into the roles of particles in the protein aggregation pathway. J Pharm Sci 100 (2): 492-503.
24. Wuchner K, Buchler J, Spycher R, Dalmonte P, Volkin DB,. 2010. Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation. J Pharm Sci 99 (8): 3343-3361.
25. Strehl R, Rombach-Riegraf V, Diez M, Egodage K, Bluemel M, Jeschke M, Koulov A,. 2011. Discrimination between silicone oil droplets and protein aggregates in biopharmaceuticals: A novel multiparametric image filter for sub-visible particles in microflow imaging analysis. J Pharm Res 29 (2): 594-602.
26. Zolls S, Gregoritza M, Tantipolphan R, Wiggenhorn M, Winter G, Friess W, Hawe A,. 2013. How subvisible particles become invisible-relevance of the refractive index for protein particle analysis. J Pharm Sci 102 (5): 1434-1446.
27. Sharma DK, Oma P, Pollo MJ, Sukumar M,. 2010. Quantification and characterization of subvisible proteinaceous particles in opalescent mAb formulations using micro-flow imaging. J Pharm Sci 99 (6): 2628-2642.
28. Patel AR, Lau D, Liu J,. 2012. Quantification and characterization of micrometer and submicrometer subvisible particles in protein therapeutics by use of a suspended microchannel resonator. Anal Chem 84 (15): 6833-6840.
29. Weinbuch D, Zolls S, Wiggenhorn M, Friess W, Winter G, Jiskoot W, Hawe A,. 2013. Micro-flow imaging and resonant mass measurement (archimedes)- Complementary methods to quantitatively differentiate protein particles and silicone oil droplets. J Pharm Sci 102 (7): 2152-2165.
30. Maddux NR, Joshi SB, Volkin DB, Ralston JP, Middaugh CR,. 2011. Multidimensional methods for the formulation of biopharmaceuticals and vaccines. J Pharm Sci 100 (10): 4171-4197.
31. Clark NR, Ma'ayan A,. 2011. Introduction to statistical methods to analyze large data sets: Principal components analysis. Sci Signal 4 (190):tr3.
32. Cheng W, Joshi SB, He F, Brems DN, He B, Kerwin BA, Volkin DB, Middaugh CR,. 2012. Comparison of high-throughput biophysical methods to identify stabilizing excipients for a model IgG2 monoclonal antibody: Conformational stability and kinetic aggregation measurements. J Pharm Sci 101 (5): 1701-1720.
33. Bhambhani A, Kissmann JM, Joshi SB, Volkin DB, Kashi RS, Middaugh CR,. 2012. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions. J Pharm Sci 101 (3): 1120-1135.
34. Thakkar SV, Joshi SB, Jones ME, Sathish HA, Bishop SM, Volkin DB, Middaugh CR,. 2012. Excipients differentially influence the conformational stability and pretransition dynamics of two IgG1 monoclonal antibodies. J Pharm Sci 101 (9): 3062-3077.
35. Iyer V, Maddux N, Hu L, Cheng W, Youssef AK, Winter G, Joshi SB, Volkin DB, Middaugh CR,. 2013. Comparative signature diagrams to evaluate biophysical data for differences in protein structure across various formulations. J Pharm Sci 102 (1): 43-51.
36. Kim JH, Iyer V, Joshi SB, Volkin DB, Middaugh CR,. 2012. Improved data visualization techniques for analyzing macromolecule structural changes. Protein Sci 21 (10): 1540-1553.
37. Manikwar P, Majumdar R, Hickey JM, Thakkar SV, Samra HS, Sathish HA, Bishop SM, Middaugh CR, Weis DD, Volkin DB,. 2013. Correlating excipient effects on conformational and storage stability of an IgG1 monoclonal antibody with local dynamics as measured by hydrogen/deuterium-exchange mass spectrometry. J Pharm Sci 102 (7): 2136-2151.
38. Bond MD, Panek ME, Zhang Z, Wang D, Mehndiratta P, Zhao H, Gunton K, Ni A, Nedved ML, Burman S, Volkin DB,. 2010. Evaluation of a dual-wavelength size exclusion HPLC method with improved sensitivity to detect protein aggregates and its use to better characterize degradation pathways of an IgG1 monoclonal antibody. J Pharm Sci 99 (6): 2582-2597.
39. Fischer H, Polikarpov I, Craievich AF,. 2004. Average protein density is a molecular-weight-dependent function. Protein Sci 13 (10): 2825-2828.
40. Simler BR, Hui G, Dahl JE, Perez-Ramirez B,. 2012. Mechanistic complexity of subvisible particle formation: Links to protein aggregation are highly specific. J Pharm Sci 101 (11): 4140-4154.
41. Burg TP, Godin M, Knudsen SM, Shen W, Carlson G, Foster JS, Babcock K, Manalis SR,. 2007. Weighing of biomolecules, single cells and single nanoparticles in fluid. Nature 446 (7139): 1066-1069.
42. Quillin ML, Matthews BW,. 2000. Accurate calculation of the density of proteins. Acta Crystallogr D Biol Crystallogr 56 (Pt 7): 791-794.
43. Wilson GA, Manning MC,. 2013. Flow imaging: Moving toward best practices for subvisible particle quantitation in protein products. J Pharm Sci 102 (3): 1133-1134.
44. Lubiniecki A, Volkin DB, Federici M, Bond MD, Nedved ML, Hendricks L, Mehndiratta P, Bruner M, Burman S, Dalmonte P, Kline J, Ni A, Panek ME, Pikounis B, Powers G, Vafa O, Siegel R,. 2011. Comparability assessments of process and product changes made during development of two different monoclonal antibodies. Biologicals 39 (1): 9-22.
45. Federici M, Lubiniecki A, Manikwar P, Volkin DB,. 2013. Analytical lessons learned from selected therapeutic protein drug comparability studies. Biologicals 41 (3): 131-147.
46. Gerhardt A, Bonam K, Bee JS, Carpenter JF, Randolph TW,. 2013. Ionic strength affects tertiary structure and aggregation propensity of a monoclonal antibody adsorbed to silicone oil-water interfaces. J Pharm Sci 102 (2): 429-440.
47. Li J, Pinnamaneni S, Quan Y, Jaiswal A, Andersson FI, Zhang X,. 2012. Mechanistic understanding of protein-silicone oil interactions. Pharm Res 29 (6): 1689-1697.
48. Seidl A, Hainzl O, Richter M, Fischer R, Bohm S, Deutel B, Hartinger M, Windisch J, Casadevall N, London GM, Macdougall I,. 2012. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res 29 (6): 1454-1467.
49. Razinkov VI, Treuheit MJ, Becker GW,. 2013. Methods of high throughput biophysical characterization in biopharmaceutical development. Curr Drug Discov Technol 10 (1): 59-70.
50. Samra HS, He F,. 2012. Advancements in high throughput biophysical technologies: Applications for characterization and screening during early formulation development of monoclonal antibodies. Mol Pharm 9 (4): 696-707.